Acromegaly
Conditions
Keywords
Acromegaly,, water retention, myocardial fibrosis, left ventricular hypertrophy, left ventricular dysfunction
Brief summary
In this study, the investigators will evaluate the cardiac structure and function, focusing on the myocardial water content and interstitial fibrosis, in patients with active acromegaly in comparison with 1) healthy volunteers, 2) the same acromegalic patients that have received efficient therapy. The investigators hypothesize that the myocardial water content in acromegaly is increased as these patients present with sodium and water retention and that this myocardial water infiltration will improve with efficient treatment of the disease. They will thus assess using CMRI, this parameter by measuring the myocardial transverse relaxation time (T2), reflecting water content in the myocardium.
Detailed description
Patients with acromegaly have left ventricular (LV) hypertrophy and dysfunction on echocardiography, but only very few studies have been performed using cardiac magnetic resonance imaging (CMRI), currently the reference modality is assessment in cardiac geometry function. In addition, no data are available on right ventricular (RV) and atrial structure and function. The pathophysiology of the cardiac involvement in acromegaly may be related to increase myocardiac water content and/or interstitial myocardiac fibrosis. The main objective of sthe study is to compare the myocardial water content in patients with acromegaly and in healthy volunteers. Secondary objectives of the study are to evaluate : 1. interstitial fibrosis and the structure and the function of LV and RV in acromegalic patients in comparison with healthy volunteers; 2. the reversibility of the cardiac involvement (water content, fibrosis, LV and RV structure and function) after efficient treatment of acromegaly; 3. the elasticity of aorta in acromegalic patients in comparison with healthy volunteers and with the post-treatment state. Twenty acromegalic patients will be included in order to dispose of 15 patients that will completed the study and the same number of age- and BMI-adjusted healthy volunteers will be included.
Interventions
DEVICECMRI
Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
DRUGGadolinium
gadolinium injection will be performed during CMRI in patients and healthy volunteers.
PROCEDUREOGTT
Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
Sponsors
Pfizer
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Active acromegaly as defined by the usual diagnostic criteria (de novo patients or patients uncontrolled by previous treatments). * Healthy volunteers matched for age, sex and BMI with the patients of the group 1
Exclusion criteria
* History of coronary heart disease (acute or chronic myocardial ischemia) * Acute or chronic renal failure (creatinin clearance 30 mL/min/l,73m2) * Contraindication of MRI * Hypersensitivity to gadolinium * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Myocardial transverse relaxation time (T2), reflecting water content assessed by CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | This outcome will be compared between patients and healthy volunteers. |
| Change from baseline Myocardial transverse relaxation time (T2) at 6 months, reflecting water content assessed by CMRI | Baseline and 6 months after beginning of the treatment in acromegalic patients | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac morphology will also be assessed CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | — |
| Function including Left Ventricular mass index will also be assessed CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | — |
| Function including Left Auricular ejection fractions will also be assessed CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | — |
| Function including Left Ventricular ejection fractions will also be assessed CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | — |
| Dense myocardial fibrosis | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | The dense myocardial fibrosis will be depicted by late gadolinium enhancement. |
| Function including Left Ventricular and Right Ventricular stroke volumes will also be assessed CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | — |
| Change from baseline Dense myocardial fibrosis at 6 months | Baseline and 6 months after beginning of the treatment in acromegalic patients | The dense myocardial fibrosis will be depicted by late gadolinium enhancement. |
| Change from baseline interstitial myocardial fibrosis at 6 months | Baseline and 6 months after beginning of the treatment in acromegalic patients | — |
| Function including Right Ventricular ejection fractions will also be assessed CMRI | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | — |
| Interstitial myocardial fibrosis | Baseline in acromegalic patients; at the 1 day evaluation visit in healthy volunteers | Interstitial myocardial fibrosis will be quantified by T1 measurements before and after gadolinium injection. |
Countries
France
Outcome results
None listed